文献速递肝病消化道出血

非酒精性脂肪性肝病与新发主要不良心血管事件:全国性组织学队列研究

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
PubMed 文献 · Gut · 2021-09-06

中位随访13.6年,NAFLD患者主要不良心血管事件(MACE)发生率显著高于对照(24.3 vs 16.0/1000人年),且风险随NAFLD严重程度增加。

要点

  • 组织学确诊NAFLD患者MACE风险显著增加(aHR 1.63)。
  • MACE风险随NAFLD严重程度进展而升高,肝硬化风险最高。
  • NAFLD患者心血管死亡风险亦显著增加(aHR 1.37)。

核心结论

  • 与匹配的对照人群相比,活检证实的NAFLD患者MACE发生率显著更高,包括缺血性心脏病、卒中、充血性心力衰竭和心血管死亡。
  • 超额风险在所有NAFLD阶段均存在,并随疾病严重程度恶化而增加。

研究设计与样本

  • NAFLD按组织病理学分为单纯性脂肪变、非纤维化性脂肪性肝炎、非肝硬化性纤维化和肝硬化。
  • 采用Cox比例风险模型计算多变量校正风险比(aHR)和95%置信区间(CI)。

主要发现

  • NAFLD患者MACE发生率高于对照(24.3 vs 16.0/1000人年;差值=8.3/1000人年;aHR 1.63,95%CI 1.56-1.70)。
  • 缺血性心脏病发生率差值=4.2/1000人年(aHR 1.64,95%CI 1.54-1.75)。
  • 充血性心力衰竭发生率差值=3.3/1000人年(aHR 1.75,95%CI 1.63-1.87)。
  • 卒中和心血管死亡分别:差值=2.4/1000人年(aHR 1.58,95%CI 1.46-1.71)和差值=1.2/1000人年(aHR 1.37,95%CI 1.27-1.48)。

临床怎么用

  • 对组织学确诊的NAFLD患者,应评估并管理心血管风险,尤其注意缺血性心脏病、心力衰竭和卒中。
  • NAFLD严重程度越高,心血管风险越大,肝硬化患者需加强心血管监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Some data suggest a positive association between non-alcoholic fatty liver disease (NAFLD) and incident major adverse cardiovascular events (MACEs). However, data are lacking from large cohorts with liver histology, which remains the gold standard for staging NAFLD severity. DESIGN: This population-based cohort included all Swedish adults with histologically confirmed NAFLD and without cardiovascular disease (CVD) at baseline (1966-2016, n=10 422). NAFLD was defined from prospectively recorded histopathology and categorised as simple steatosis, non-fibrotic steatohepatitis, non-cirrhotic fibrosis and cirrhosis. Patients with NAFLD were matched to ≤5 population controls without NAFLD or CVD, by age, sex, calendar year and county (n=46 517). Using Cox proportional hazards modelling, we calculated multivariable adjusted HRs (aHRs) and 95% CIs for MACE outcomes (ie, ischaemic heart disease (IHD), stroke, congestive heart failure (CHF) or cardiovascular (CV) mortality). RESULTS: Over a median of 13.6 years, incident MACE was confirmed in 2850 patients with NAFLD and 10 648 controls. Patients with NAFLD had higher incidence of MACE than controls (24.3 vs 16.0/1000 person-years (PY); difference=8.3/1000 PY; aHR 1.63, 95% CI 1.56 to 1.70), including higher rates of IHD (difference=4.2/1000 PY; aHR 1.64, 95% CI 1.54 to 1.75), CHF (difference=3.3/1000 PY; aHR 1.75, 95% CI 1.63 to 1.87), stroke (difference=2.4/1000 PY; aHR 1.58, 95% CI 1.46 to 1.71) and CV mortality (difference=1.2/1000 PY; aHR 1.37, 95% CI 1.27 to 1.48). Rates of incident MACE increased progressively with worsening NAFLD severity (ptrend=0.02), with the highest incidence observed with cirrhosis (difference vs controls=27.2/1000 PY; aHR 2.15, 95% CI 1.77 to 2.61). CONCLUSION: Compared with matched population controls, patients with biopsy-proven NAFLD had significantly higher incidence of MACE, including IHD, stroke, CHF and CV mortality. Excess risk was evident across all stages of NAFLD and increased with worsening disease severity.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Simon TG, Roelstraete B, Hagström H, et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2021. PMID: 34489307. doi:10.1136/gutjnl-2021-325724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。